Working...
ClinicalTrials.gov
ClinicalTrials.gov Menu

Study of Dasatinib in Combination With Everolimus for Children and Young Adults With Gliomas Harboring PDGFR Alterations

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT03352427
Recruitment Status : Recruiting
First Posted : November 24, 2017
Last Update Posted : May 17, 2019
Sponsor:
Information provided by (Responsible Party):
University of Michigan Rogel Cancer Center

Brief Summary:
This trial will evaluate the activity of dasatinib in combination with everolimus for children with gliomas harboring PDGFR alterations, including newly diagnosed high-grade glioma (HGG) or diffuse intrinsic pontine glioma (DIPG) after radiation (stratum A); and recurrent/progressive glioma (grade II-IV, including DIPG) (stratum B).

Condition or disease Intervention/treatment Phase
Glioma High Grade Glioma Pontine Tumors Drug: Dasatinib Drug: Everolimus Phase 2

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 32 participants
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Phase 2 Study of Dasatinib in Combination With Everolimus for Children With Gliomas Harboring PDGFR Alterations
Actual Study Start Date : December 6, 2017
Estimated Primary Completion Date : December 2023
Estimated Study Completion Date : December 2024

Resource links provided by the National Library of Medicine


Arm Intervention/treatment
Experimental: Dasatinib+Everolimus

Dasatinib = 60 mg/m2 orally twice daily

Everolimus = starting dose of 3.0 mg/m2, with titration of dosing after first cycle to keep everolimus trough level of 5-15 ug/ml

Both agents will be taken daily for 28 day cycles. Cycles will be repeated every 28 days and patients may receive up to 24 cycles.

Drug: Dasatinib
60 mg/m2 orally twice daily

Drug: Everolimus
3.0 mg/m2, with titration of dosing after first cycle to keep trough level of 5-15 ug/ml




Primary Outcome Measures :
  1. Progression-free survival in participants with newly diagnosed diffuse intrinsic pontine glioma (DIPG) [ Time Frame: 8 months ]
    Percentage of participants without progression, defined as 25% increase in the size of the tumor or appearance of new lesions.

  2. Progression-free survival in participants with newly diagnosed high-grade glioma (HGG) [ Time Frame: 12 months ]
    Percentage of participants without progression, defined as 25% increase in the size of the tumor or appearance of new lesions.

  3. Overall response rate (OR) (partial response or better) in participants with refractory or recurrent glioma [ Time Frame: 56 Days ]
    The overall response assessment will take into account response in both target and non-target lesions, as well as the appearance of new lesions. Partial Response (PR) will be defined as ≥50% decrease in size of tumor in comparison to baseline measurements. Complete Response (CR) will be defined as The disappearance of all abnormal signal. This includes return to normal size of the brainstem for brainstem lesions.


Secondary Outcome Measures :
  1. Overall Survival [ Time Frame: 1 year ]
  2. Overall Survival [ Time Frame: 2 years ]


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   1 Year to 50 Years   (Child, Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Histological confirmation of a newly diagnosed high-grade glioma or diffuse intrinsic pontine glioma (DIPG) (Stratum A)
  • Histological confirmation (at diagnosis or relapse) of a recurrent or progressive grade II-IV glioma (including DIPG) (Stratum B)
  • Participants must have a genomic (DNA and/or RNA) alteration (mutation, fusion, and/or amplification) involving PDGF-A, PDGF-B, PDGFR-A or PDGFR-B, as identified by tumor sequencing.
  • Age at enrollment: Greater than 1 year and less than 50 years
  • BSA (body surface area): BSA greater than 0.3 m2
  • Karnofsky (Measure of performance for cancer patients where 100% represents perfect health) > 50% for patients > 16 years of age and Lansky (Measure of performance for pediatric cancer patients where 100% represents perfect health) > 50% for patients < 16 years of age. Neurologic deficits in patients with CNS tumors must have been relatively stable for a minimum of 7 days. Patients who are unable to walk because of paralysis, but who are able to sit in a wheelchair, will be considered ambulatory for the purpose of assessing the performance score.
  • Adequate bone marrow function per protocol
  • Adequate liver function per protocol
  • Adequate renal and metabolic function per protocol
  • Patients with known seizure disorder must have seizures adequately controlled with non- enzyme inducing antiepileptic medications
  • No increase in steroid dose within the past 7 days
  • Primary brain or spine tumor are eligible, including tumors with metastases, multiple lesions.
  • Patients must have fully recovered from the acute toxic effects of all prior chemotherapy, immunotherapy, or radiotherapy.
  • Myelosuppressive chemotherapy: Must not have received within 3 weeks.
  • Hematopoietic growth factors: At least 7 days since the completion of therapy with a growth factor, 14 days for long- acting.
  • Biologic (anti-neoplastic agent): At least 7 days or 3 half-lives (whichever is longer) since the completion of therapy.
  • Radiation therapy:

    • Stratum A: ≥ 2 weeks and </= to 12 weeks must have elapsed from radiation.
    • Stratum B: ≥ 2 weeks must have elapsed from focal radiation.
  • > 3 weeks from major surgery. If recent craniotomy, adequate wound healing must be determined by neurosurgical team.
  • Autologous Stem Cell Transplant or Rescue: No evidence of active graft vs. host disease and ≥ 4 weeks must have elapsed.
  • All patients and/or a legal guardian must sign institutionally approved written informed consent and assent documents.

Exclusion Criteria:

  • Patients who are breastfeeding, pregnant or refuse to use an effective form of birth control are excluded.
  • Patients with uncontrolled infection are excluded.
  • Patients receiving other anti-neoplastic agents are excluded.
  • Patients requiring strong CYP3A4 or PGP inhibitors are excluded (per protocol)
  • Patients requiring anticoagulation or with uncontrolled bleeding are excluded.
  • Patients on steroids for symptom management must be on a stable dose for 7 days prior to start of treatment.
  • Patients within 1 year of allogeneic stem cell transplant, patients with active GVHD or requiring immunosuppression are excluded.
  • Previous hypersensitivity to rapamycin or rapamycin derivatives

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03352427


Contacts
Layout table for location contacts
Contact: Carl Koschmann, M.D. 734-936-9814 ckoschma@med.umich.edu

Locations
Layout table for location information
United States, Michigan
University of Michigan Cancer Center Recruiting
Ann Arbor, Michigan, United States, 48109
Contact: Carl Koschmann, M.D.    734-615-2736    ckoschma@umich.edu   
Principal Investigator: Carl Koschmann, MD         
Sponsors and Collaborators
University of Michigan Rogel Cancer Center
Investigators
Layout table for investigator information
Principal Investigator: Carl Koschmann, M.D. University of Michigan Rogel Cancer Center

Layout table for additonal information
Responsible Party: University of Michigan Rogel Cancer Center
ClinicalTrials.gov Identifier: NCT03352427     History of Changes
Other Study ID Numbers: UMCC 2017.042
HUM00123094 ( Other Identifier: University of Michigan )
First Posted: November 24, 2017    Key Record Dates
Last Update Posted: May 17, 2019
Last Verified: May 2019
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No

Additional relevant MeSH terms:
Layout table for MeSH terms
Glioma
Brain Stem Neoplasms
Neoplasms, Neuroepithelial
Neuroectodermal Tumors
Neoplasms, Germ Cell and Embryonal
Neoplasms by Histologic Type
Neoplasms
Neoplasms, Glandular and Epithelial
Neoplasms, Nerve Tissue
Infratentorial Neoplasms
Brain Neoplasms
Central Nervous System Neoplasms
Nervous System Neoplasms
Neoplasms by Site
Brain Diseases
Central Nervous System Diseases
Nervous System Diseases
Everolimus
Sirolimus
Dasatinib
Antineoplastic Agents
Immunosuppressive Agents
Immunologic Factors
Physiological Effects of Drugs
Anti-Bacterial Agents
Anti-Infective Agents
Antibiotics, Antineoplastic
Antifungal Agents
Protein Kinase Inhibitors
Enzyme Inhibitors